Clinical trials: Metastatic Colorectal Cancer, completed
BRAF V600E Mutation Positive, Metastatic Colorectal Cancer
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in patients with mCRC, and findings from clinical trials have largely remained inconclusive regarding the efficacy of first line treatments for…
- Trial name
- CAPSTAN CRC (NCT04317599)
- Testing
- Non interventional
- Where
- 34 sites in Austria, Belgium and 5 more
- Volunteers
- 274 people
- Sponsor
- Pierre Fabre Medicament
Metastatic Colorectal Cancer
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type…
- Trial name
- TAILOR (NCT01228734)
- Testing
- Cetuximab, Oxaliplatin, Folinic Acid
- Where
- 25 sites in China
- Volunteers
- 553 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer, Skin Rash
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with…
- Conditions
- Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer
- Trial name
- STEPP (NCT00332163)
- Testing
- Panitumumab, Irinotecan, FOLFIRI
- Volunteers
- 95 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
This trial will evaluate the efficacy and safety of the capecitabine and oxaliplatine plus bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer.
- Trial name
- NCT01024504
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 6 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and immune response of different doses of RNF43-721 emulsified with Montanide ISA 51 in combination with S-1/CPT-11 chemotherapy.
- Trial name
- NCT00641615
- Testing
- RNF43-721
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Kazuhiko Yoshimatsu
Metastatic Colorectal Cancer
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
The purpose of this study is to assess the safety and anti-tumor activity of the triple combination of WNT974, LGX818 and cetuximab in BRAFV600-mutant mCRC with RNF43 mutations or RSPO fusions.
- Trial name
- NCT02278133
- Testing
- WNT974, LGX818, Cetuximab
- Where
- 19 sites in United States, Australia and 8 more
- Volunteers
- 20 people
- Sponsor
- Array BioPharma
Antineoplastic Agents
Erbitux MEtastatic Colorectal Cancer Strategy Study
To investigate whether cetuximab alone (given until progression or cumulative toxicity) after 8 cycles of FOLFIRI + cetuximab results in a non inferior Progression Free Survival when compared with continuous FOLFIRI + cetuximab…
- Trial name
- NCT02484833
- Testing
- Cetuximab, FOLFIRI
- Where
- Italy
- Volunteers
- 607 people
- Sponsor
- Armando Orlandi
Colorectal Cancer, Colon Cancer
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms
- Trial name
- NCT00041652
- Testing
- hMN14 (labetuzumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Metastatic Cancer, Melanoma
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
- Conditions
- Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- ConsortiumIO (NCT04208958)
- Testing
- VE800, Nivolumab, Vancomycin Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 56 people
- Sponsor
- Vedanta Biosciences, Inc.
Colorectal Cancer (CRC)
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and…
- Trial name
- CodeBreak300 (NCT05198934)
- Testing
- Sotorasib, Panitumumab, Trifluridine and Tipiracil
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Colorectal Cancer
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic…
- Trial name
- NCT01378143
- Testing
- OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
- Where
- 7 sites in Canada
- Volunteers
- 53 people
- Sponsor
- Oncozyme Pharma Inc.
Neoplasms, Colorectal
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for…
- Trial name
- NCT00540943
- Testing
- Pazopanib, Cetuximab, Irinotecan
- Where
- 2 sites in France
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Colorectal Adenocarcinoma, RAS Wild Type
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally…
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02292758
- Testing
- Bevacizumab, Cetuximab, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and…
- Trial name
- NCT00113776
- Testing
- ABX-EGF
- Sponsor
- Amgen
Metastatic Colorectal Cancer
Study of IMC-11F8 in Participants With Colorectal Cancer
The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).
- Trial name
- NCT00835185
- Testing
- IMC-11F8 (necitumumab), Oxaliplatin, Folinic acid (FA)
- Where
- 5 sites in Belgium, Spain
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
ColoRectal Cancer, Liver Metastases
Simultaneous Resection of Colorectal Cancer With Synchronous Liver Metastases
Synchronous colorectal cancer with liver metastases, defined as the diagnosis of a primary colorectal tumour and liver metastases within 12 months, is a common problem faced by colorectal and hepatobiliary surgeons.(Adam) The…
- Conditions
- ColoRectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Surgery
- Trial name
- RESECT (NCT02954913)
- Testing
- Simultaneous Resection
- Where
- 2 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Hamilton Health Sciences Corporation
Colorectal Cancer, Metastatic Cancer
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an…
- Trial name
- NCT00656123
- Testing
- Colon GVAX, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Kidney Cancer
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030342
- Testing
- recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Luke's Medical Center
Metastatic Colorectal Cancer
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine.
- Trial name
- NCT00514761
- Testing
- AZD6244, Capecitabine
- Where
- 3 sites in Brazil
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.